Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial

view article

Published at: biz.yahoo.com

There is a hope for NHL ( Non-Hodgkin's Lymphoma).

August 21, 2008

Analysis by: GLG Expert Contributor

1. BiovaxID®  is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. 2. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells   3. BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma. 4. Phase III trial results  are very encouraging.

Donald TsaiAssociate Professor of Medicine University of Pennsylvania Cancer Center

BiovaxID: Does It Work?

August 15, 2008

1) BiovaxID shows a 100% improvement in DFS at 3 years (p=0.24) 2) BiovaxID shows an improvement in median overall DFS with a significant P value (p=0.047) 2) This is the first lymphoma vaccine with a suggestion of activity. 3) BiovaxID shows evidence of activity despite the failure of 2 other lymphoma vaccines made by Genitiope and Favrille.